Ignite Creation Date:
2025-12-24 @ 6:45 PM
Ignite Modification Date:
2026-02-11 @ 3:19 PM
Study NCT ID:
NCT00618657
Status:
COMPLETED
Last Update Posted:
2024-02-28
First Post:
2008-02-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Sponsor:
University of California, Irvine
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
20076084
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None